Treprostinil Sodium

CAS: 289480-64-4

Ref. 3D-PLA48064

Product Information

• Name: Treprostinil Sodium
• Synonyms: ({(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid, Acetic acid, (((1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((3S)-3-hydroxyoctyl)-1H-benz(f)inden-5-yl)oxy)-, monosodium salt, Acetic acid, 2-[[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]-, sodium salt (1:1), Remodulin, Trepulmix, UT 15 (pharmaceutical), Unii-7Jz75N2Nt6, Ut 15, sodium ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetate, sodium ({(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetate

Description

Treprostinil is a drug that belongs to the family of coumarin derivatives. It is used in the treatment of pulmonary arterial hypertension. Treprostinil has been shown to have long-term efficacy and it does not cause significant side effects. The drug has been tested for safety and efficacy in clinical trials with patients with congestive heart failure and HIV infection, as well as in models of diabetic neuropathy and Parkinson's disease. Treprostinil is metabolized by cytochrome P450 enzymes and eliminated by renal excretion. The pharmacokinetics of treprostinil are dose-dependent, with higher doses leading to increased plasma concentrations. Treprostinil also binds to dopamine receptors on cells, which may lead to its therapeutic effects on Parkinson's disease symptoms.

• Brand: Biosynth

Chemical properties

• Molecular weight: 412.49 g/mol
• Formula: C₂₃H₃₃NaO₅
• Purity: Min. 95%